Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
Retrieved on:
Thursday, October 20, 2022
General Health, Pharmaceutical, Health, Clinical Trials, National Institutes of Health, Degenerative disease, QIDP, Infection, Diarrhea, TOC, Genetically modified bacteria, Treatment, Test, Administration, National, Gram-positive bacteria, CEO, Bacteria, Pyelonephritis, MDR, United States Department of Health and Human Services, Urinary tract infection, Biomedical Advanced Research and Development Authority, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-negative bacteria, BARDA, Company, Department, Medication, CRE, FDA, AP, National Institute, Hypertension, Constipation, Nausea, Human services, LFU, Cefepime, Headache, Cutis marmorata, Wellcome Trust, New Drug Application, Patient, Food, BLI, Complicated, Adult, National Institute of Allergy and Infectious Diseases, Medical microbiology, Pseudomonas aeruginosa, Melioidosis, Pharmaceutical industry, Antibiotics, Safety, Meropenem
Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.
Key Points:
- Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.
- The presentations, along with the four other posters detailing additional cefepime-taniborbactam data at IDWeek 2022 (see release ), will be available on the companys website.
- We believe this data is meaningful given the sustained clinical benefit versus meropenem up to 3 to 4 weeks after treatment, said Christopher J. Burns, Ph.D. , President and CEO of Venatorx.
- The safety data for cefepime-taniborbactam was consistent with the historical safety data for cefepime.